HK1101348A1 - Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation - Google Patents

Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Info

Publication number
HK1101348A1
HK1101348A1 HK07106150.6A HK07106150A HK1101348A1 HK 1101348 A1 HK1101348 A1 HK 1101348A1 HK 07106150 A HK07106150 A HK 07106150A HK 1101348 A1 HK1101348 A1 HK 1101348A1
Authority
HK
Hong Kong
Prior art keywords
cancer
antibodies
methods
cancer cell
cell proliferation
Prior art date
Application number
HK07106150.6A
Other languages
English (en)
Inventor
Vanitha Ramakrishnan
Vinay Bhaskar
Sun Ho
Richard Murray
Debbie Law
Original Assignee
Abbott Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotherapeutics Corp filed Critical Abbott Biotherapeutics Corp
Publication of HK1101348A1 publication Critical patent/HK1101348A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK07106150.6A 2004-03-24 2007-06-08 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation HK1101348A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55642104P 2004-03-24 2004-03-24
US55642204P 2004-03-24 2004-03-24
US62504904P 2004-11-03 2004-11-03
US65109805P 2005-02-07 2005-02-07
US65751405P 2005-02-28 2005-02-28
PCT/US2005/009939 WO2005092073A2 (en) 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Publications (1)

Publication Number Publication Date
HK1101348A1 true HK1101348A1 (en) 2007-10-18

Family

ID=35056776

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07106150.6A HK1101348A1 (en) 2004-03-24 2007-06-08 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Country Status (15)

Country Link
US (2) US7662384B2 (ja)
EP (1) EP1755659B1 (ja)
JP (1) JP4857259B2 (ja)
KR (1) KR20070009637A (ja)
AT (1) ATE531388T1 (ja)
AU (1) AU2005226736B2 (ja)
BR (1) BRPI0509177A (ja)
CA (1) CA2560508A1 (ja)
DK (1) DK1755659T3 (ja)
ES (1) ES2376556T3 (ja)
HK (1) HK1101348A1 (ja)
IL (1) IL178042A (ja)
NO (1) NO20064794L (ja)
NZ (1) NZ549893A (ja)
WO (1) WO2005092073A2 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2359834T1 (sl) 2006-03-15 2017-02-28 Alexion Pharmaceuticals, Inc. Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa
NZ571068A (en) * 2006-03-21 2012-06-29 Genentech Inc An antibody that can bind human alpha5beta1
WO2007114851A1 (en) * 2006-04-04 2007-10-11 The Board Of Trustees Of The University Of Illinois Methods and compositions to induce cell death of invasive tumors
CA2652886A1 (en) * 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity
US20100150931A1 (en) * 2006-11-22 2010-06-17 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
MX2010000997A (es) * 2007-07-27 2010-03-31 Facet Biotech Corp Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b).
CL2008002856A1 (es) 2007-09-26 2009-01-16 Genentech Inc Anticuerpo novedoso (anticuerpo anti-integrina a5b1; mol}ecula de ácido nucleico que lo codifica; vector y célula huesped; método de producción; composición farmacéutica que lo comprende; su uso para inhibir la angiogénesis y/o permeabilidad vascular y cáncer entre otras patologías; y método de detección de la integrina a5b1).
AU2009212442C1 (en) * 2008-02-05 2014-07-17 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
TWI504409B (zh) * 2009-03-25 2015-10-21 Genentech Inc 新穎抗－α５β１抗體及其用途
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
PE20141413A1 (es) 2011-10-25 2014-10-25 Onclave Therapeutics Ltd Formulaciones de anticuerpo y metodos
US8946159B2 (en) 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
NO2760138T3 (ja) 2012-10-01 2018-08-04
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618871A4 (en) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704366A (en) * 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3854306B2 (ja) * 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
NZ249677A (en) * 1992-02-19 1996-08-27 Schering Corp Monoclonal antibodies and compositions useful for treating il-4 diseases and intermediates for making such antibodies
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE250138T1 (de) 1992-10-29 2003-10-15 Univ Australian Angiogenese-inhibierende antikörper
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP0704920B1 (en) * 1994-09-21 2000-04-19 Matsushita Electric Industrial Co., Ltd. Solid-state lithium secondary battery
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
WO1997033887A1 (en) 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5846536A (en) 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
WO1998032771A1 (fr) 1997-01-29 1998-07-30 Toray Industries, Inc. Proteines chimeres, complexes heterodimeres de ces proteines et substituant de plaquette
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
CA2330277A1 (en) 1998-04-27 1999-11-04 Sidney Kimmel Cancer Center Reduced complexity nucleic acid targets and methods of using same
WO1999058139A2 (en) * 1998-05-08 1999-11-18 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
AU6902200A (en) 1999-08-11 2001-03-05 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
WO2001053297A1 (en) 2000-01-20 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
WO2001053262A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US20040259152A1 (en) * 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
JP2004531249A (ja) 2001-02-14 2004-10-14 プロテイン デザイン ラブス インコーポレイティド 血管新生の診断方法、組成物、及び血管新生モジュレータのスクリーニング方法
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
JP4741242B2 (ja) * 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
US20050002930A1 (en) * 2003-04-03 2005-01-06 Johnson Dale E. Methods of production and use of anti-integrin antibodies for the control of tissue granulation
KR20060080535A (ko) * 2003-05-14 2006-07-10 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물

Also Published As

Publication number Publication date
IL178042A (en) 2011-05-31
EP1755659A2 (en) 2007-02-28
ES2376556T3 (es) 2012-03-14
US20050260210A1 (en) 2005-11-24
DK1755659T3 (da) 2012-02-27
AU2005226736A1 (en) 2005-10-06
EP1755659A4 (en) 2008-08-20
BRPI0509177A (pt) 2007-09-18
CA2560508A1 (en) 2005-10-06
ATE531388T1 (de) 2011-11-15
NZ549893A (en) 2010-05-28
WO2005092073A2 (en) 2005-10-06
US20100291111A1 (en) 2010-11-18
WO2005092073A3 (en) 2006-08-10
NO20064794L (no) 2006-10-23
KR20070009637A (ko) 2007-01-18
JP2007530584A (ja) 2007-11-01
US7662384B2 (en) 2010-02-16
JP4857259B2 (ja) 2012-01-18
AU2005226736B2 (en) 2009-11-26
EP1755659B1 (en) 2011-11-02
IL178042A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
IL178042A0 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
EP1708752A4 (en) THERAPEUTIC CANCER WITH POLYMER-BONDED ANTIBODY
EA200601433A1 (ru) Способы и композиции для лечения опухолей и метастазирования
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
DE602005027617D1 (de) Radiotherapiebehandlungsüberwachung unter einsatz von ultraschall
EA200801853A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
MXPA02011379A (es) Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
IL180725A0 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
WO2004000094A8 (en) Predictive markers in cancer therapy
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
DE60027768D1 (de) Behandlung von metastatischer krankheit
WO2006097743A3 (en) Method for actvating natural killer cells by tumor cell preparation in vitro
WO2008083326A3 (en) Targeting of ews-fli1 as anti-tumor therapy
HK1116186A1 (en) Azaxanthones and use thereof for treating tumors
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
WO2020107002A3 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
MX2019015194A (es) Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas.
MXPA03003011A (es) Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
UA88294C2 (ru) ПРИМЕНЕНИЕ АНТИ-α5β1 АНТИТЕЛ ДЛЯ УГНЕТЕНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
ATE392210T1 (de) Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160324